Literature DB >> 23795239

L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ

Jo-Anne Pinson1, Zhaohua Zheng, Michelle S Miller, David K Chalmers, Ian G Jennings, Philip E Thompson.   

Abstract

A series of aminoacyl-triazine derivatives based upon the pan-PI3K inhibitor ZSTK474 were identified as potent and isoform selective inhibitors of PI3Kβ. The compounds showed selectivity based upon stereochemistry with L-amino acyl derivatives preferring PI3Kβ while their D-congeners favoured PI3Kδ. The mechanistic basis of this inhibition was studied using site-directed mutants. One Asp residue, D862 was identified as a critical participant in binding to the PI3Kβ-selective inhibitors distinguishing this class from other reported PI3Kβ-selective inhibitors. The compounds show strong inhibition of cellular Akt phosphorylation and growth of PTEN-deficient MD-MBA-468 cells.

Entities:  

Keywords:  PI3 kinase; ZSTK474; cancer; p110β

Year:  2013        PMID: 23795239      PMCID: PMC3688631          DOI: 10.1021/ml300336j

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

Authors:  Sarah A Meadows; Francisco Vega; Adam Kashishian; Dave Johnson; Volker Diehl; Langdon L Miller; Anas Younes; Brian J Lannutti
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

2.  Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.

Authors:  Shin-ichi Yaguchi; Yasuhisa Fukui; Ichiro Koshimizu; Hisashi Yoshimi; Toshiyuki Matsuno; Hiroaki Gouda; Shuichi Hirono; Kanami Yamazaki; Takao Yamori
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

3.  PI 3-kinase p110beta: a new target for antithrombotic therapy.

Authors:  Shaun P Jackson; Simone M Schoenwaelder; Isaac Goncalves; Warwick S Nesbitt; Cindy L Yap; Christine E Wright; Vijaya Kenche; Karen E Anderson; Sacha M Dopheide; Yuping Yuan; Sharelle A Sturgeon; Hishani Prabaharan; Philip E Thompson; Gregg D Smith; Peter R Shepherd; Nathalie Daniele; Suhasini Kulkarni; Belinda Abbott; Dilek Saylik; Catherine Jones; Lucy Lu; Simon Giuliano; Sascha C Hughan; James A Angus; Alan D Robertson; Hatem H Salem
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

4.  Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.

Authors:  Hong Lin; Mark J Schulz; Ren Xie; Jin Zeng; Juan I Luengo; Michael D Squire; Rosanna Tedesco; Junya Qu; Karl Erhard; James F Mack; Kaushik Raha; Ramona Plant; Cynthia M Rominger; Jennifer L Ariazi; Christian S Sherk; Michael D Schaber; Jeanelle McSurdy-Freed; Michael D Spengler; Charles B Davis; Mary Ann Hardwicke; Ralph A Rivero
Journal:  ACS Med Chem Lett       Date:  2012-05-29       Impact factor: 4.345

5.  Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

Authors:  Montserrat Camps; Thomas Rückle; Hong Ji; Vittoria Ardissone; Felix Rintelen; Jeffrey Shaw; Chiara Ferrandi; Christian Chabert; Corine Gillieron; Bernard Françon; Thierry Martin; Denise Gretener; Dominique Perrin; Didier Leroy; Pierre-Alain Vitte; Emilio Hirsch; Matthias P Wymann; Rocco Cirillo; Matthias K Schwarz; Christian Rommel
Journal:  Nat Med       Date:  2005-08-28       Impact factor: 53.440

6.  Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives.

Authors:  T Matsuno; M Karo; H Sasahara; T Watanabe; M Inaba; M Takahashi; S I Yaguchi; K Yoshioka; M Sakato; S Kawashima
Journal:  Chem Pharm Bull (Tokyo)       Date:  2000-11       Impact factor: 1.645

7.  Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism.

Authors:  Xuxiao Zhang; Oscar Vadas; Olga Perisic; Karen E Anderson; Jonathan Clark; Phillip T Hawkins; Len R Stephens; Roger L Williams
Journal:  Mol Cell       Date:  2011-03-04       Impact factor: 17.970

Review 8.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

9.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

Review 10.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

View more
  4 in total

1.  The pyrrolidinoindoline alkaloid Psm2 inhibits platelet aggregation and thrombus formation by affecting PI3K/Akt signaling.

Authors:  Xing-Li Su; Wen Su; Ying Wang; Yue-Hu Wang; Xin Ming; Yi Kong
Journal:  Acta Pharmacol Sin       Date:  2016-07-18       Impact factor: 6.150

Review 2.  Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Authors:  Yu Liu; Wen-Zhu Wan; Yan Li; Guan-Lian Zhou; Xin-Guang Liu
Journal:  Oncotarget       Date:  2017-01-24

3.  Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.

Authors:  Ayman A M Alameen; Carolina Simioni; Alberto M Martelli; Giorgio Zauli; Simona Ultimo; James A McCubrey; Arianna Gonelli; Giorgia Marisi; Paola Ulivi; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2016-08-23

4.  A new triazine bearing a pyrazolone group capable of copper, nickel, and zinc chelation.

Authors:  Akop Yepremyan; Arshad Mehmood; Samantha Brewer; Madalyn M Barnett; Benjamin G Janesko; Giridhar Akkaraju; Eric E Simanek; Kayla N Green
Journal:  RSC Adv       Date:  2018-01-16       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.